Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« K. C. Nicolaou on Drug Discovery | Main | An Easy Way to Make Cyclic Peptides »

July 16, 2014

What Structures Have Turned on You?

Email This Entry

Posted by Derek

When you ask a bunch of medicinal chemists to look over a list of structures - screening hits, potential additions to the compound collection, that sort of thing - you'll find that everyone will cross some of them off. But the agreement between the chemists on which ones need to go, that's the tough part. It's been shown that we don't overlap very much in our preferences, at least when it comes to the structures we'd prefer not to try to advance. That's because we don't overlap as well as we think we do when it comes to the rules we're using.

So here's a question, which might illustrate the point: what compound classes or scaffolds have you been burned by? I think that's one big factor that we all use when we're evaluating one of those compound lists - which ones are in that "Fooled me once" category? For me, a recent experience with NH pyrroles has me reluctant to go there again. And I'm not interested in things with napthalenes hanging off of them, naproxen notwithstanding. I'd also rather not see Mannich products, since I've personally seen a number of those misbehave.

So what's on your list? I think that everyone can agree on things like rhodanines, although even those have their partisans. But what semi-decent looking compounds will you go ahead and blackball, based on your own nasty experiences with them?

Comments (17) + TrackBacks (0) | Category: Life in the Drug Labs


COMMENTS

1. road on July 16, 2014 9:15 AM writes...

I first read the title as "What Structures Have Turned You On" and was expecting a much more interesting post!

Permalink to Comment

2. Anchor on July 16, 2014 9:33 AM writes...

Thioureas! Enough said!

Permalink to Comment

3. Kazoochemist on July 16, 2014 9:44 AM writes...

Not an answer to your query, but I would like to direct the readers to my prior comment on the paper you refer to in the first paragraph. It is comment number four in the "as we think we do" link. The premise of the work described in the paper as well as the reported results and conclusions are deeply flawed. This is a consequence of the way the lists of compounds were pre-sorted and the selection guidelines given to the reviewing chemists.

Permalink to Comment

4. Anonymous on July 16, 2014 10:40 AM writes...

Indazoles on grounds of promiscuity springs to mind.

Permalink to Comment

5. anon the II on July 16, 2014 10:57 AM writes...

I also read the title like Mr. Road (#1) and thought that might be a better column. Jonathan Baell (of PAINS fame) has kinda covered this already. And we mostly agree with what he said plus a few more here and there. So how 'bout a column on what structures that turn us on? Not pharmacologically, but for purely aesthetic appeal.

Permalink to Comment

6. Anonymous on July 16, 2014 11:29 AM writes...

Dimethyl pyrroles.

Permalink to Comment

7. Anonymous on July 16, 2014 12:17 PM writes...

Phenethyl amines, tryptamines. Oh wait. Never mind.

Permalink to Comment

8. Industry Guy on July 16, 2014 12:39 PM writes...

Anything that turns up in the Patent Gazette that I'm currently working on I consider having turned on me....those compounds have no loyalty...

Permalink to Comment

9. John Wayne on July 16, 2014 3:57 PM writes...

Thiazoles, heteroaryl ketones, and anything that has to be greasy for activity/brain penetration

Permalink to Comment

10. Secondaire on July 16, 2014 7:14 PM writes...

Imidazoles, with all of their "let's inhibit heme-containing anything!" activity.

Permalink to Comment

11. Anonymous on July 16, 2014 9:35 PM writes...

imidazole for me too!

Permalink to Comment

12. Anonymous on July 16, 2014 9:35 PM writes...

imidazole for me too!

Permalink to Comment

13. Deep Lurker on July 17, 2014 12:56 AM writes...

Back before I took my extra-early retirement, I was willing to go with all kinds of different iffy things. Because you never know, and in my case I did work with some really grotty compounds.

But I was a lot less enthusiastic than my boss about heavily fluorinated compounds, and a lot more enthusiastic about t-butyl groups.

Permalink to Comment

14. exGlaxoid on July 17, 2014 8:51 AM writes...

I have always liked indoles, piperidines, pyridyls, N-benzyl and phenethyl groups, phenols, CF3s, and even naphthylenes. My turnoffs are carbazoles (all of the problems of both indoles and naphthyls) furans (although a few have worked OK), guanadines (Arg is a pain), polymethoxybenzenes, hydrazones, and steriods (although they are in many useful drugs). Like Derek, I also don't like pyrroles. And thioureas, thioamides, and thioketones are all bad.

Permalink to Comment

15. Iridium on July 17, 2014 4:26 PM writes...

At one point I worked on a series with a tetrahydro thienopyridine core, which exhibited extremely interesting activity in our primary assay. However, after several months of working with a CRO (little to no internal chemistry) we discovered that the compounds auto-oxidized to the pyridiniums while just sitting on the bench in solid form. Was able to demonstrate that the activity in the assay was linked to the ability of the compound to form the pyridinium. Was never too happy about that...

Permalink to Comment

16. Lunar landing on July 22, 2014 6:10 PM writes...

Thiophenes

Permalink to Comment

17. Bill Curatolo on August 8, 2014 12:47 PM writes...

Hydantoins.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Worst Seminar
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All